The page below is a sample from the LabCE course Tumor Markers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tumor Markers (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 94 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Prostate-Specific Antigen (PSA): Controversy

Despite the decreased mortality of prostate cancer since the advent of PSA as a screening tool, a high degree of scrutiny has arisen over the number of unnecessary biopsies and subsequent testing related to false positive PSA tests.3-4
Some of this controversy relates directly to the fact that PSA also is found to be elevated in common, non-malignant conditions of the prostate, including prostatitis and benign prostatic hypertrophy (BPH). Others have argued that not all prostate cancers are associated with a high degree of mortality, and that if well-contained within the prostate, are not a cause for surgical intervention to remove the tumor or perform a prostatectomy.5-6
Despite its shortcomings, PSA remains one of the most ordered cancer screening tests.3